German biotech company MorphoSys buys US rival for $1.7B
Germany-based MorphoSys AG said Wednesday that it is buying U.S. rival Constellation Pharmaceuticals Inc. in a deal valuing the biotech company at $1.7 billion.
- Next story France widens COVID vaccine drive to 12 to 18-year-olds
- Previous story Vaccine protection may diminish need for yearly boosters
Explore more
- COVID-19 mother-to-newborn infection rates are low, but indirect risks exist
At the start of the COVID-19 pandemic, very little was known about... - Here’s The Latest News on the Colonial Pipeline Shutdown
The national average for a gallon of regular gasoline rose 2 cents... - Super Resolution dramatically increases frame rates, but doesn’t require AMD GPU
AMD launched FidelityFX Super Resolution during its Computex 2021 keynote, promising to... - Wealth Tax, Capitol Hill, Watermelon Season: Your Tuesday Evening Briefing
Here’s what you need to know at the end of the day. - People are panic buying homes as prices skyrocket around the world
It wasn’t long ago that real estate experts were bracing for the... - Trump wants people to boycott Coke. His properties are still serving it
Over the past few years former President Donald Trump has called for... - Transgender teens may turn to substance use to cope with stress
Over half of transgender or gender minority (GM) adolescents engage in substance... - Round 1 NFL Draft Order and Picks: Here Are the Results
Trevor Lawrence was taken with the first pick by the Jacksonville Jaguars. - Spike in severe pediatric type 2 diabetes complication during COVID-19 pandemic
According to the Centers for Disease Control and Prevention (CDC), children generally... - Low doses of radiation may improve quality of life for those with severe Alzheimer’s
Individuals living with severe Alzheimer’s disease showed remarkable improvements in behavior and...